한국형 우울장애 약물치료 알고리듬 2021 (V): 안전성, 부작용, 동반 신체질환을 고려한 항우울제 선택 및 치료저항성 우울증의 임상적 정의
Korean Medication Algorithm Project for Depressive Disorder 2021 (V): Antidepressant Choices According to Safety, Adverse Effect, Comorbid Physical Illnesses and Clinical Definition of Treatment Resistant Depression
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives To revise Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAPDD 2017) guidelines by revising antidepressant choices based on their safety, adverse effects, comorbid physical illnesses, and the clinical definition of treatment-resistant depression (TRD). Methods A 33-item questionnaire comprised of six parts was developed. A 65-expert consensus (65/97, 67.0%) was obtained on pharmacological treatment strategies regarding antidepressant choice with respect to safety, adverse effects, and comorbid physical illnesses. Multiple response sets were subjected to statistical analysis. Results The results obtained showed that first-line pharmacotherapeutic strategies based on various clinical considerations were as follows: mirtazapine (for patients with increased suicidality, Gastrointestinal discomfort, and insomnia), bupropion (for patients with orthostatic hypotension, history of a safety accident, serotonin syndrome, sedation, sexual dysfunction, and weight gain), and escitalopram (for patients with anticholinergic side effects). For patients exhibiting comorbid conditions, duloxetine was the first line pharmacotherapeutic strategy for chronic pain, escitalopram was the first-line pharmacotherapeutic strategy for diabetes, hypertension, liver disease, Parkinson’s disease, renal disease, epilepsy, and thyroid disease, and sertraline was a first-line pharmacotherapeutic strategy for arrhythmia and cardiovascular disease. Conclusion Pharmacological treatment strategy of KMAP-DD 2021 is similar to that of KMAPDD 2017. Additional study is required to determine antidepressant choices for TRD and cancer patients with depression.
Abstract
Objectives To revise Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAPDD 2017) guidelines by revising antidepressant choices based on their safety, adverse effects, comorbid physical illnesses, and the clinical definition of treatment-resistant depression (TRD). Methods A 33-item questionnaire comprised of six parts was developed. A 65-expert consensus (65/97, 67.0%) was obtained on pharmacological treatment strategies regarding antidepressant choice with respect to safety, adverse effects, and comorbid physical illnesses. Multiple response sets were subjected to statistical analysis. Results The results obtained showed that first-line pharmacotherapeutic strategies based on various clinical considerations were as follows: mirtazapine (for patients with increased suicidality, Gastrointestinal discomfort, and insomnia), bupropion (for patients with orthostatic hypotension, history of a safety accident, serotonin syndrome, sedation, sexual dysfunction, and weight gain), and escitalopram (for patients with anticholinergic side effects). For patients exhibiting comorbid conditions, duloxetine was the first line pharmacotherapeutic strategy for chronic pain, escitalopram was the first-line pharmacotherapeutic strategy for diabetes, hypertension, liver disease, Parkinson’s disease, renal disease, epilepsy, and thyroid disease, and sertraline was a first-line pharmacotherapeutic strategy for arrhythmia and cardiovascular disease. Conclusion Pharmacological treatment strategy of KMAP-DD 2021 is similar to that of KMAPDD 2017. Additional study is required to determine antidepressant choices for TRD and cancer patients with depression.
참고문헌 (22)
- Cipriani A, "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis", Lancet, 391, pp.1357~1366 (2018)
- Sirey JA, "Adherence to depression treatment in primary care : a randomized clinical trial", JAMA Psychiatry, 74, pp.1129~1135 (2017)
- Khaledi M, "The prevalence of comorbid depression in patients with type 2 diabetes : an updated systematic review and meta-analysis on huge number of observational studies", Acta Diabetol, 56, pp.631~650 (2019)
- Kim JM, "Physical comorbidity and 12-week treatment outcomes in Korean patients with depressive disorders: the CRESCEND study", J Psychosom Res, 71, pp.311~318 (2011)
- Stommel M, "Depression and functional status as predictors of death among cancer patients", Cancer, 94, pp.2719~2727 (2002)
- Thase ME, "Managing medical comorbidities in patients with depression to improve prognosis", J Clin Psychiatry, 77(Suppl 1), pp.22~27 (2016)
- VA, "DoD clinical practice guideline for the management of major depressive disorder", Management of Major Depressive Disorder Working Group, 2016
- Depression:the treatment and management of depression in adults, "National Collaborating Centre for Mental Health(NICE)", British Psychological Society, ~ (2010)
- Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
- 이정구, "한국형 우울장애 약물치료 알고리듬 2017(Ⅵ) : 안정성, 부작용, 동반 신체질환을 고려한 항우울제 선택", Mood and Emotion, 15(2), pp.103~109 (2017), 대한우울조울병학회
- Pollock BG, "Adverse reactions of antidepressants in elderly patients", J Clin Psychiatry, 60(Suppl 20), pp.4~8 (1999)
- Carvalho AF, "The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature", Psychother Psychosom, 85, pp.270~288 (2016)
- Arterburn D, "Long-term weight change after initiating secondgeneration antidepressants", J Clin Med, 5, pp.48~ (2016)
- Alonso-Pedrero L, "Effects of antidepressant and antipsychotic use on weight gain : a systematic review", Obes Rev, 20, pp.1680~1690 (2019)
- Nezafati MH, "Antidepressants and cardiovascular adverse events : a narrative review", ARYA Atheroscler, 11, pp.295~304 (2015)
- Pacher P, "Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?", Curr Med Chem, 6, pp.469~480 (1999)
- Hesslinger B, "Comorbidity of depressive disorders and cardiovascular diseases. Implications for diagnosis, pharmaco- and psychotherapy", Nervenarzt, 73, pp.205~217 (2002)
- Ojero-Senard A, "A comparative study of QT prolongation with serotonin reuptake inhibitors", Psychopharmacology(Berl), 234, pp.3075~3081 (2017)
- Lunn MP, "Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia", Cochrane Database Syst Rev, (1) (2014)
- Al-Harbi KS, "Treatment-resistant depression: therapeutic trends, challenges, and future directions", Patient Prefer Adherence, 6, pp.369~388 (2012)
- Berman RM, "Treatment-refractory depression : definitions and characteristics", Depress Anxiety, 5, pp.154~164 (1997)
- Rybak YE, "Treatment-resistant major depressive disorder:Canadian expert consensus on definition and assessment", Depress Anxiety, 38, pp.456~467 (2021)